Moderna shares jump 11.15% as personalized cancer vaccine data reaches ESMO Congress
AI Summary- Moderna said three intismeran autogene abstracts were accepted for presentation at the ESMO Congress.
- Shares rose 11.15% to $171.21, nearing the 52-week high of $176.66.
- The INTerpath-001 Phase 3 melanoma data will be presented on October 24.